4.7 Review

Update on blepharospasm -: Report from the BEBRF International Workshop

期刊

NEUROLOGY
卷 71, 期 16, 页码 1275-1282

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/01.wnl.0000327601.46315.85

关键词

-

资金

  1. NIH Intramural Program
  2. Control of eyelids in normal and pathological states [EY07391]
  3. Advanced Neuromodulation Systems
  4. Allergan, Inc.
  5. Boehringer-Ingelheim
  6. Ceregene, Inc.
  7. EMD
  8. Eisai
  9. Ipsen Limited
  10. Huntington's Disease Society of America
  11. Kyowa Pharmaceuticals
  12. Medtronic
  13. Merz Pharmaceuticals
  14. National Institutes of Health
  15. National Parkinson Foundation
  16. Novartis
  17. Ortho-McNeil
  18. Parkinson Study Group
  19. Prestwick Pharmaceuticals
  20. Schering
  21. Schwarz Pharma/UCB
  22. Teva

向作者/读者索取更多资源

This review updates understanding and research on blepharospasm, a subtype of focal dystonia. Topics covered include clinical aspects, pathology, pathophysiology, animal models, dry eye, photophobia, epidemiology, genetics, and treatment. Blepharospasm should be differentiated from apraxia of eyelid opening. New insights into pathology and pathophysiology are derived from different types of imaging, including magnetic resonance studies. Physiologic studies indicate increased plasticity and trigeminal sensitization. While botulinum neurotoxin injections are the mainstay of therapy, other therapies are on the horizon.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据